What are the effects of NOACs versus warfarin in Asians compared to non-Asians?
A recent meta-analysis of 5 NOAC trials found that for standard-dose NOACs (dabigatran 150 mg, rivaroxaban 20 mg, apixaban 5 mg, and edoxaban 60 mg), the effect sizes of the primary efficacy endpoint (stroke and systemic embolism) and the primary safety endpoint (major bleeding) were greater in Asians compared to non-Asians.